Clinical Trials Browser

Phase 3 × Has announcements × 130-nm albumin-bound paclitaxel × Clear all

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Phase 3 Active not recruiting

644 enrolled 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04083235 2026-04-20

NAPOLI 3

Phase 3 Completed

770 enrolled 13 charts 1 FDA

Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 1 FDA

Breast

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase 3 Active not recruiting

381 enrolled 1 FDA

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

882 enrolled 41 charts 1 FDA

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

Phase 3 Completed

559 enrolled 18 charts 1 FDA

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Phase 3 Completed

902 enrolled 27 charts 1 FDA

Breast

Triple Negative Breast Neoplasms

NCT02367781 2021-08-09

IMpower130

Phase 3 Completed

723 enrolled 28 charts 1 FDA

Tumor-Agnostic

Carcinoma